Trial NCT04641481
Publication Ella R, Lancet, 2021
Primary outcome on the report: Efficacy of the BBV152 vaccine in preventing a first occurrence of symptomatic COVID-19(any severity)with onset at least 14 days after the second dose in the per-protocol populationcomposed of participants who were SARS-CoV-2 negative by PCR and serology at baseline,had no major protocol deviations, and followed-up for at least two weeks after the second dose.

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.